First-of-Its-Kind Cancer Therapy Targets ‘Undruggable’ Protein Interaction - Phoenix Bioscience Core

First-of-Its-Kind Cancer Therapy Targets ‘Undruggable’ Protein Interaction - Phoenix Bioscience Core

Facebook Twitter LinkedIn Email Print Timothy Marlowe, PhD, and Lauren Reyes are studying a new therapy that disrupts the connection between two key proteins in cancer cells. Phoenix scientists pioneer a new cancer therapy by disrupting a protein link that helps tumors survive and spread A groundbreaking cancer therapy being developed in Phoenix is rewriting the rules of drug discovery by targeting what scientists have long considered “undruggab…